Marcello Deraco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9359420/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology, 2006, 13, 229-237.	1.5	144
2	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. Gynecologic Oncology, 2011, 122, 215-220.	1.4	131
3	Consensus statement on peritoneal mesothelioma. Journal of Surgical Oncology, 2008, 98, 268-272.	1.7	92
4	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. Tumori, 2001, 87, 120-126.	1.1	77
5	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2018, 25, 404-413.	1.5	61
6	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Annals of Surgical Oncology, 2018, 25, 1184-1192.	1.5	30
7	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. Surgical Oncology Clinics of North America, 2018, 27, 507-517.	1.5	27
8	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Annals of Surgical Oncology, 2020, 27, 98-106.	1.5	26
9	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 2021, 47, 2888-2892.	1.0	26
10	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World Journal of Gastrointestinal Oncology, 2010, 2, 76.	2.0	22
11	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 2021, 47, 1132-1139.	1.0	12
12	Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo, 2006, 20, 773-6.	1.3	12
13	Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. European Journal of Surgical Oncology, 2022, 48, 1590-1597.	1.0	6
14	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. Tumori, 2010, 96, 340-344.	1.1	3
15	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
16	Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. European Journal of Surgical Oncology, 2021, 47, 164-171.	1.0	2
17	Fertility preservation in women with peritoneal surface malignancies: A case series. European Journal of Surgical Oncology, 2021, 47, 2948-2951.	1.0	2